Literature DB >> 21364113

Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy.

Joseph L Blackshear1, Hartzell V Schaff, Steve R Ommen, Dong Chen, William L Nichols.   

Abstract

Bleeding with severe aortic stenosis is linked to acquired von Willebrand syndrome and loss of high-molecular-weight multimers of von Willebrand factor. Valve replacement resolves bleeding tendency and loss of high-molecular-weight multimers. We report outcomes in 5 patients with symptomatic obstructive hypertrophic cardiomyopathy and spontaneous gastrointestinal, mucosal, or excessive postsurgical bleeding in whom acquired von Willebrand syndrome was documented. All 5 patients underwent surgical septal myectomy with resolution of acquired von Willebrand syndrome.

Entities:  

Mesh:

Year:  2011        PMID: 21364113      PMCID: PMC3046942          DOI: 10.4065/mcp.2010.0309

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  24 in total

Review 1.  Acquired von Willebrand syndrome: from pathophysiology to management.

Authors:  A Veyradier; C S Jenkins; E Fressinaud; D Meyer
Journal:  Thromb Haemost       Date:  2000-08       Impact factor: 5.249

Review 2.  Diffuse angiodysplasia of the upper gastrointestinal tract in a patient with hypertrophic obstructive cardiomyopathy.

Authors:  H Fujita; J Tomiyama; Y Chuganji; M Momoi; T Tanaka
Journal:  Intern Med       Date:  2000-05       Impact factor: 1.271

3.  Acquired von Willebrand syndrome in children with patent ductus arteriosus.

Authors:  R Rauch; U Budde; A Koch; M Girisch; M Hofbeck
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

4.  Cardiac disease and recurrent gastrointestinal bleeding: angiodysplasia with accompanying hypertrophic subaortic stenosis.

Authors:  D J Kimmel; S B Paster; J Burstein; J Stovring; P T Cochran
Journal:  Rocky Mt Med J       Date:  1977 Nov-Dec

5.  Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis.

Authors:  F I Pareti; A Lattuada; C Bressi; M Zanobini; A Sala; A Steffan; Z M Ruggeri
Journal:  Circulation       Date:  2000-09-12       Impact factor: 29.690

6.  Plasma von Willebrand factor multimer quantitative analysis by in-gel immunostaining and infrared fluorescent imaging.

Authors:  Rajiv K Pruthi; Todd M Daniels; John A Heit; Dong Chen; Whyte G Owen; William L Nichols
Journal:  Thromb Res       Date:  2010-12       Impact factor: 3.944

Review 7.  Acquired von Willebrand disease.

Authors:  Shaji Kumar; Rajiv K Pruthi; William L Nichols
Journal:  Mayo Clin Proc       Date:  2002-02       Impact factor: 7.616

Review 8.  Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome.

Authors:  Theodore E Warkentin; Jane C Moore; Sonia S Anand; Eva M Lonn; David G Morgan
Journal:  Transfus Med Rev       Date:  2003-10

9.  Acquired von Willebrand syndrome in aortic stenosis.

Authors:  André Vincentelli; Sophie Susen; Thierry Le Tourneau; Isabelle Six; Olivier Fabre; Francis Juthier; Anne Bauters; Christophe Decoene; Jenny Goudemand; Alain Prat; Brigitte Jude
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

10.  Septal alcohol ablation and Heyde's syndrome revisited.

Authors:  P Riis Hansen; C Hassager
Journal:  J Intern Med       Date:  2003-04       Impact factor: 8.989

View more
  10 in total

1.  Hypertrophic obstructive cardiomyopathy, acquired von Willebrand syndrome, and gastrointestinal bleeding.

Authors:  Rajiv K Pruthi
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

2.  A case of hypertrophic obstructive cardiomyopathy and acquired von Willebrand syndrome: response to medical therapy.

Authors:  Masaki Wake; Nobuyuki Takahashi; Hiroyuki Yoshitomi; Kazuaki Tanabe
Journal:  J Echocardiogr       Date:  2014-05-10

3.  Indexes of von Willebrand factor as biomarkers of aortic stenosis severity (from the Biomarkers of Aortic Stenosis Severity [BASS] study).

Authors:  Joseph L Blackshear; Ewa M Wysokinska; Robert E Safford; Colleen S Thomas; Mark E Stark; Brian P Shapiro; Steven Ung; Gretchen S Johns; Dong Chen
Journal:  Am J Cardiol       Date:  2012-11-17       Impact factor: 2.778

4.  A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER.

Authors:  Ryan Hunt; Ayla Yalamanoglu; James Tumlin; Tal Schiller; Jin Hyen Baek; Andrew Wu; Agnes B Fogo; Haichun Yang; Edward Wong; Peter Miller; Paul W Buehler; Chava Kimchi-Sarfaty
Journal:  Blood       Date:  2016-11-18       Impact factor: 22.113

Review 5.  Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians.

Authors:  Radha Mehta; Muhammad Athar; Sameh Girgis; Atif Hassan; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2019-07       Impact factor: 2.300

Review 6.  Gastrointestinal Bleeding in Native and Prosthetic Valve Disease.

Authors:  Joseph L Blackshear
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-02-03

7.  Heyde's syndrome: exploring the link between aortic stenosis and an acquired bleeding disorder.

Authors:  David Ledingham
Journal:  BMJ Case Rep       Date:  2013-04-18

8.  Acquired von Willebrand Syndrome and Chronic Anaemia: A Different Diagnostic Approach.

Authors:  Nuno Zarcos Palma; Mariana da Cruz; Gisela Evaristo Vasconcelos; Vítor Fagundes; Lindora Pires; Mari Mesquita
Journal:  Eur J Case Rep Intern Med       Date:  2019-06-10

9.  Severe Gastrointestinal Bleeding in a Patient With Subvalvular Aortic Stenosis Treated With Thalidomide and Octreotide: Bridging to Transcoronary Ablation of Septal Hypertrophy.

Authors:  Helene S Hvid-Jensen; Steen H Poulsen; Jorgen S Agnholt
Journal:  J Clin Med Res       Date:  2015-09-25

Review 10.  Shear Stress-Induced Activation of von Willebrand Factor and Cardiovascular Pathology.

Authors:  Sergey Okhota; Ivan Melnikov; Yuliya Avtaeva; Sergey Kozlov; Zufar Gabbasov
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.